0001564590-20-050850.txt : 20201105 0001564590-20-050850.hdr.sgml : 20201105 20201105070556 ACCESSION NUMBER: 0001564590-20-050850 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 201288625 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-8k_20201105.htm 8-K eypt-8k_20201105.htm
false 0001314102 0001314102 2020-11-05 2020-11-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2020

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

000-51122

 

26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of

each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


 

Item 2.02. Results of Operations and Financial Condition.

 

On November 5, 2020, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. 

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1

  

Press Release of EyePoint Pharmaceuticals, Inc., dated November 5, 2020

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EyePoint Pharmaceuticals, Inc.

 

 

Date: November 5, 2020

 

By:

 

/s/ George O. Elston

 

 

Name:

 

George O. Elston

 

 

Title

 

Chief Financial Officer and Head of Corporate Development

 

 

EX-99.1 2 eypt-ex991_54.htm EX-99.1 eypt-ex991_54.htm

 

Exhibit 99.1

 

EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments

 

- Total revenues of $15.7 million and net product revenues of $5.8 million -

 

- Sequential quarterly increase in underlying customer demand of over 120% for DEXYCU® and over 5% for YUTIQ® -

 

- EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration, remains on track for Q4 IND filing -

 

- CRG debt facility amended, waiving and modifying net product revenue covenants for 2020 and 2021, respectively -

 

- Cash as of October 31, 2020 at $30.5 Million -

 

- Management to host a conference call and webcast today at 8:30 AM ET -

 

WATERTOWN, Mass., November 5, 2020 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced financial results for the third quarter ended September 30, 2020 and highlighted recent corporate developments.

 

“With the continued increase in patient office visits and resumption of operations at many healthcare facilities during the quarter, we were encouraged to see customer demand for both YUTIQ® and DEXYCU® near pre-COVID-19 pandemic levels,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “We enter the remaining months of 2020 with the EyePoint and ImprimisRx combined sales teams mobilized to promote DEXYCU to their established account base and our YUTIQ team continuing to call on uveitis and retinal physician offices, subject to evolving COVID-19-related restrictions.”

 

Ms. Lurker continued, “With the recent completion of our good laboratory practice (GLP) toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wet AMD), we remain on track to submit an Investigational New Drug (IND) application before the end of the year. Upon acceptance of the IND by the U.S. Food and Drug Administration (FDA), we look forward to initiating a Phase 1 trial of EYP-1901 in wet AMD, a sight-threatening eye disease that is in significant need of longer-

 


 

lasting treatment options that may slow its progression. In addition, we continue to diligently manage our cash and burn rate and ended October 31, 2020 with $30.5 million in cash.

 

Commercial Performance in Third Quarter 2020

 

Customer demand for YUTIQ, represented as units purchased by physicians from the Company’s distributors, was approximately 450 units in Q3 2020 as compared to approximately 430 units in Q2 2020.

 

Customer demand for DEXYCU, represented as units purchased by ambulatory surgery centers (ASCs) from the Company’s distributors, was approximately 4,700 units in Q3 2020 as compared to approximately 2,100 units in Q2 2020.

 

Separate purchasing and marketing agreements for expanded access to DEXYCU across the U.S. were recently executed with Vantage Outsourcing and another undisclosed healthcare network. The Company is actively negotiating agreements with additional group purchasing organizations and networks.

 

In August, the Company and ImprimisRx signed a commercial alliance for the joint promotion of DEXYCU in the U.S. which more than doubles the size of our team engaging directly with physicians and ASCs. During September, ImprimisRx’s sales specialists and inside sales team completed product training and are positioned to call on their ophthalmologist, hospital and ASC accounts.

 

The Company continues to actively monitor the COVID-19 pandemic and associated public health recommendations to ensure the safety of our patients, physicians and employees.

 

Operations Update

 

In October, based in part on the return in customer demand for both products following COVID-19-related closures, the Company secured an amendment to its existing debt facility with CRG Servicing LLC (CRG) in which CRG waived the covenant associated with the Company’s net product revenue for DEXYCU and YUTIQ for the twelve-month period ending on December 31, 2020. CRG also agreed to a reduction of the calendar year 2021 net product revenue covenant to $45 million from $80 million. There were no other material changes made to the term loan agreement and the Company incurred no incremental charges in connection with the amendment.

 

In August, the Company and Ocumension Therapeutics announced an expansion of their exclusive license agreements for YUTIQ and DEXYCU in certain markets in Asia. Under the expanded agreements, Ocumension made a one-time $9.5 million payment to EyePoint for rights to commercialize both products under its own brand names in South Korea and other jurisdictions across Southeast Asia and as the full and final payment of all remaining development, regulatory, and commercial sale milestone payments under the original license agreements. Royalties for future product sales remain payable to the Company pursuant to the license agreements.

 

R&D Highlights

 

In October, the Company completed a GLP toxicology study for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its bioerodible Durasert® technology for wet AMD. The Company expects to file an IND application with the FDA in the fourth quarter of 2020 with a Phase 1 human clinical trial to commence shortly after IND acceptance by the FDA.

 


 

 

Review of Results for Third Quarter Ended September 30, 2020

For the three months ended September 30, 2020, total net revenue was $15.7 million compared to $2.5 million for the three months ended September 30, 2019. Net product revenue for the three months ended September 30, 2020 was $5.8 million, with $3.5 million for YUTIQ and $2.3 million for DEXYCU, compared to net product revenue for three months ended September 30, 2019 of $1.0 million generated primarily by DEXYCU. Net product revenue represents product purchased by EyePoint’s distributors whereas customer demand represents purchases of product by physician practices and ASCs from EyePoint’s distributors.

 

Net revenue from licenses, royalties and collaborations for the three months ended September 30, 2020 totaled $9.9 million compared to $1.5 million in the corresponding quarter in 2019.

 

Operating expenses for the three months ended September 30, 2020 totaled $17.7 million compared to $16.6 million in the prior year period. This increase was driven by a $1.6 million increase in cost of sales, a $1.4 million increase in G&A expense and $0.6 million increase in R&D expense being offset by a $2.5 million reduction in sales and marketing expense. Non-operating expense, net, for the three months ended September 30, 2020 totaled $1.8 million of net interest expense. Net loss for the three months ended September 30, 2020 was $3.8 million, or $0.03 per share, compared to a net loss of $15.6 million, or $0.15 per share, for the prior year quarter.

 

Review of Nine Months Results Ended September 30, 2020

For the nine months ended September 30, 2020, total net revenue was $27.3 million compared to $11.7 million for the nine months ended September 30, 2019. Net product revenue for the nine months ended September 30, 2020 was $14.2 million, compared to net product revenues for the nine months ended September 30, 2019 of $8.9 million.

 

Net revenue from royalties and collaborations for the nine months ended September 30, 2020 totaled $13.2 million compared to $2.8 million in the corresponding period in 2019.

 

Operating expenses for the nine months ended September 30, 2020 totaled $51.9 million from $50.6 million in the prior year period. This increase was primarily due to a $2.0 million increase in cost of sales, a $1.0 million increase in R&D expense and a $1.2 million increase in G&A expense offset by a $2.9 million decrease in sales and marketing expense. Non-operating expense, net, for the nine months ended September 30, 2020 totaled $5.4 million. Net loss for the nine months ended September 30, 2020 was $29.9 million, or $0.24 per share, compared to a net loss of $46.4 million, or $0.45 per share, for the prior year period.

 

Cash and cash equivalents at October 31, 2020 totaled $30.5 million compared to $28.7 million at September 30, 2020 and $22.2 million at December 31, 2019.

 

Financial Outlook

We expect that the Company’s cash and cash equivalents combined with projected cash inflows from anticipated YUTIQ and DEXYCU product sales and other expected financing activities can fund the Company’s operating plan into 2021 assuming no significant increase in COVID-19-related closures that would materially affect the frequency of ophthalmology office visits or the number of cataract surgical procedures performed across the U.S.

 

 


 

The Company continues to assess additional cash conservation and generation measures to support its operations through the COVID-19 pandemic.

 

Conference Call Information

EyePoint will host a conference call today, Thursday, November 5, 2020, at 8:30 AM ET to discuss the results for the third quarter ended September 30, 2020 and recent operational developments. To access the conference call, please dial (877) 312-7507 from the U.S. and Canada or (631) 813-4828 (international) at least 10 minutes prior to the start time and refer to conference ID 1452724. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website.

 

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

 

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for wet age-related macular degeneration. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic

 


 

macular edema, or DME; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

 

Contacts

Investors:
Argot Partners

Sam Martin or Joe Rayne

212-600-1902

eyepoint@argotpartners.com

 

Media:
Thomas Gibson

201-476-0322
tom@tomgibsoncommunications.com  

 

 

 

 

 

 

 

 

 

 


 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

2020

 

2019

 

2020

 

2019

Revenues:

 

 

 

 

 

 

 

 

Product sales, net

 

$    5,758

 

$       1,009

 

$    14,151

 

$      8,941

License and collaboration agreements

 

9,535

 

1,054

 

11,590

 

1,125

Royalty income

 

402

 

446

 

1,565

 

1,666

Total revenues

 

15,695

 

2,509

 

27,306

 

11,732

Operating expenses:

 

 

 

 

 

 

 

 

Cost of sales, excluding amortization of acquired intangible assets

 

1,882

 

327

 

3,363

 

1,363

Research and development

 

4,090

 

3,484

 

12,219

 

11,237

Sales and marketing

 

5,269

 

7,778

 

19,483

 

22,373

General and administrative

 

5,796

 

4,365

 

14,949

 

13,790

Amortization of acquired intangible assets

 

615

 

615

 

1,845

 

1,845

Total operating expenses

 

17,652

 

16,569

 

51,859

 

50,608

Loss from operations

 

(1,957)

 

(14,060)

 

(24,553)

 

(38,876)

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

Interest and other income, net

 

(4)

 

183

 

58

 

692

Interest expense

 

(1,840)

 

(1,770)

 

(5,430)

 

(4,389)

Loss on extinguishment of debt

 

 

 

 

(3,810)

Total other expense, net

 

(1,844)

 

(1,587)

 

(5,372)

 

(7,507)

Net loss

 

$ (3,801)

 

$  (15,647)

 

(29,925)

 

$ (46,383)

Net loss per common share - basic and diluted

 

$    (0.03)

 

$       (0.15)

 

$      (0.24)

 

$      (0.45)

Weighted average common shares outstanding - basic and diluted

 

127,945

 

106,938

 

122,768

 

102,900

 

 

 

 

 

 

 

 

 

 

 

 

 


 

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

 

 

September 30,

 

December 31,

 

 

2020

 

2019

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$                 28,726

 

$                22,214

Accounts and other receivables, net

 

9,392

 

11,368

Prepaid expenses and other current assets

 

5,832

 

5,997

Inventory

 

3,642

 

2,138

Total current assets

 

47,592

 

41,717

Operating lease right-of-use assets

 

2,733

 

3,078

Intangible assets, net

 

25,824

 

27,669

Other assets

 

642

 

507

Total assets

 

$                  76,791

 

$                72,971

Liabilities and stockholders’ equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$                  12,030

 

$                11,024

Other current liabilities

 

597

 

481

Deferred revenue

 

300

 

15

Total current liabilities

 

12,927

 

11,520

Long-term debt

 

50,775

 

47,223

Operating lease liabilities - noncurrent portion

 

2,483

 

2,898

Other long-term liabilities

 

3,012

 

3,000

Total liabilities

 

69,197

 

64,641

Stockholders’ equity:

 

 

 

 

Capital

 

501,965

 

472,776

Accumulated deficit

 

(495,211)

 

(465,286)

Accumulated other comprehensive income

 

840

 

840

Total stockholders’ equity

 

7,594

 

8,330

Total liabilities and stockholders’ equity

 

$                   76,791

 

$                72,971

 

 

GRAPHIC 3 ggg2mdj2pm2z000001.jpg GRAPHIC begin 644 ggg2mdj2pm2z000001.jpg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end EX-101.SCH 4 eypt-20201105.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information - Tagging Pending link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 eypt-20201105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 6 eypt-20201105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 eypt-8k_20201105_htm.xml IDEA: XBRL DOCUMENT 0001314102 2020-11-05 2020-11-05 false 0001314102 8-K 2020-11-05 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - Tagging Pending
Nov. 05, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 05, 2020
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Trading Symbol EYPT
Entity Emerging Growth Company false
Entity File Number 000-51122
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Entity Incorporation, State or Country Code DE
Title of 12(b) Security Common Stock, par value $0.001
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information - Tagging Pending Sheet http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending Document and Entity Information - Tagging Pending Cover 1 false false All Reports Book All Reports eypt-8k_20201105.htm eypt-20201105.xsd eypt-20201105_lab.xml eypt-20201105_pre.xml eypt-ex991_54.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eypt-8k_20201105.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "eypt-8k_20201105.htm" ] }, "labelLink": { "local": [ "eypt-20201105_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "eypt-20201105_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "eypt-20201105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20201105", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20201105.htm", "contextRef": "C_0001314102_20201105_20201105", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information - Tagging Pending", "role": "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending", "shortName": "Document and Entity Information - Tagging Pending", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "eypt-8k_20201105.htm", "contextRef": "C_0001314102_20201105_20201105", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://eyepointpharma.com/20201105/taxonomy/role/DocumentDocumentAndEntityInformationTaggingPending" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-20-050850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-050850-xbrl.zip M4$L#!!0 ( +LX95$':V:!R 0 /,6 1 97EP="TR,#(P,3$P-2YX M1*B)-,O7G*0+"=ZC#P:B M.B]CF%*\!K>$088(I.#1GO0CN&/( S>4@ID6$V"&!>;/./8JK2L1CT7I.14- M)L9,Z2N65T[#>:LYIU[&4S^6W)?K'/N*R556GV["N" M/PC"D1N$[C"T["?8V-:O\D%OBUHJ@6)N)"S%-R';LB)DSMM1:8J&=;$CP.4A M,S6IS0Y!!\P0U,*N66*Y+:%-#((@\DMB U KE!:MR@\IA'FK@S2A181!@D0[ M E"0$QZHS4JS;VA9#@RPA3[&\ MATLL89LCTSB.QTE^N M30M7;[GA0!W;4\H

BCZD4YOWZ8QP'WYAOAD&' M6'1$4@K]'#SF3=\5S_X@T#=-[!QB5NYF(CDM47:GF)Y>:4X(I6>JG2Y^:1LS MWA)/Y\2Q,C\-4>?4:1U5&X@@8YDT,,R>WAQU;1B_43CW5-PLRYZ![>"9 MH"L13*<;>%96$JF%IYILHB0^ DAKU3J!KQRABH?6D]#_?ER5"EV/NYL][:=^ M:'!U/GQ=DET*4,)5QK+END1I*\7^O6'Q9Z:PK>]4!U"R&M<33%/"T@?,]+]* M'=, 9DKX6P_A8]4;MI1OO80L!J5RT-"N"[PT "H+W4J\=Z'V[PW]2_S2W^W. MU4ZSBY=;Y1US_1]02P,$% @ NSAE4:K* \P5!P BDD !4 !E>7!T M+3(P,C Q,3 U7VQA8BYX;6S-7-UNVS88O1^P=^#$:,8QJR6FOX[3=[M&)X[B_.D[/<3( ?\6'!3)?/=!IBPGMCGN<&7@/O>]P@L#@ M,C/P^-3KP([?'9^@T126* MXPT"1 A:@FLJ3OP2#PVN""$/ @IW'P@#ABS\AO)ZA$Z-8CJ7C" MHX!'/YZU,NHM1HRT*9O81XYS;*>C6\GPQ<;XE^-HM-OM=NWHMZNA'*L&"EC7 M_OKY9N@]H2FTA%4B!9XDX+C'HYTWU(L\JE 7*!PA?[+289;<9;E'UK';7G"_ M)=0 (-:#48(>T!C([U\>!H6<75N.L ,T$<'Q;^ ($5%S!/'$T%@]CS"6FR;K MZ,HZW-]D'6]4:.%R)OJ!X^F,"%7LG4N]1:'>:MAO'Q=,#X\AK3^BS[2,LH-VN MW+#D1N9(Q*YO5T&(PV5?7((P2 :"9/$G6N;9B5S,*$MW1H=TUBJ9;.?+E./E MBBJVY-43"JPOPZI@W\AH+1X,<3IGT7);6='PM7W/8QJ0\("(" BFC_9K09OU M7S O5P5D7EJ V-Q20S+"]JBX3)B%%LF&?LSHM%3-A)9N5E]R*,XR*H^Y^.L^1J]LP^0"F[LER;?)N+9X#TQ_6 M5PFGE7*OG[G(' MD,?:VPW *PV0/(?/=*D+=)M"IBE.FHM]V'O%?.$U;A-U=.(C@_(CAN%R.J*D M:@NN36J6A!R(_J9+X$&,?_AF4PM-"[4P1E123T]]R\/5%+&)H/R#T9?PJ4^G M,QC4?%!4 +'+J4L)N;+AJ_XNPMYY("Q!RF9%NA.BU3Q22%27UQ]<7U$2X&OKB*P6,84IJL"OJV6@ >JP1]+?;9->>]:'(0S1 M';MG]!D'7LT'G$48&D1?P]Q_]"-"F?V4TK#\%QFE:@*E>*::HFZ'V(Z[*G9H M[XE[RD-(_L&S/O6;=<0:@@;I,%-N5N%7- M*AWM-$3>G(DRW*/1(PY)Y=[9G-=,]'6NYNFF:Q],#G$P^2RN9QB&E=\G5,UL>+;80-K#V7G% 5*2PP>Y1'Q: M+HU90I,&&NL([SU#LE>0$#GZ4R;YUZ_L;CRN_FRD#*&9QL6(^D,MN"PO0P9B M-A#1'3[>%>RAU40STPJR<@'TZ[NPAP88<#Y';/T1,QI=F<4 M^Z;NCP(=3?:HJ%>JV)/=<2.VY+_X27;A^-_>G/\/4$L#!!0 ( +LX95&2 M,5J;"P4 XL 5 97EP="TR,#(P,3$P-5]P&ULY5IMC^(V$/Y> MJ?_!S7VY4QN2P$:[H.5.=%\JU'U!+&U/_7(RC@'K'#NRPTO^?<>!$%C";=B[ MG'H*'R D,^/'C\?C&<>7'U8A1PNJ-).B:WD-UT)4$!DP,>U:Y[MMD:NWSD[[_ANPVLWSUS7^]5U.ZZ[8^#O=;?0SJ>#_ 8H M-'ROM2,XP.0SGE+4O]X1;)T3'_M!>W)&QV?G[OD%#BX\]\+'$]\?3WRRBU1& MB6+368S>DG(-J:9.TW5;3B9M;<17!_++5BKMM=MM)WVZ M%=6L2!#,>L['^[LG,J,AMF&HP N(:4"SCDYOWDF2CE$)7.BHA/EG9V*VN65[ M3;OE-58ZL( -A-9\*,GID$Z0^?UKV-^V21,:22;B:(95B%,W,F/@>:[O&%EG M1,.(@Q/=K?N<&ILI.NE:-(EB.Q,V[;TIDHV3"/Q>,W@"O7>^$E*,5U+(,%EC MRR9&]ML3P8V(69STQ42"KF%WA*=3F) #*LR\?*D'0S#[Z?5FCW T #@M3C-"6-J5PX 670OMY/C,>5=JYP= MIW+P7P^[:L 0%AEA,0SE/H)P M![-A+F*57,F@--Y2IBKH@EF0^6 &B=K#/!R7G_.'>A6 NP)*>I#5G4+DODYE M@]X+ EC=]$!"CL/_9='I8UULH6K J5,]JH&2"[;.S4Z'?&"C:M!F3!_52"[% MJ_#NJE<-=?,#Z0[U7@5VWT!E<$=XU0]@L6:3S1ISVO1_P4AEL&\9/S%0'>I5 M!NXFI,HDFG\HN8QGL()'6"2GX3QBH@+((X5--OR4A&-9.H%ZIE09DU?@5 KS M/B22JS_IB1P>*%<&5>A7ZX*[.1<"*LP)Y-9HQOB_N)DF$AEDUKLH@^J:",[%J>ZWIN MPW4M%($GFIR^:S4M--< 1D8&MBGCH!M0;RH:W*W[?11FBA$PC*6FJ>S_F9!G M7IXSTOK6C$ Y_ /P<20HY;SX]>2E>$G):3FO,RT'^4#.2[N>O#Q+X[9\>-\\ MT/X8?'PQ]\[9J6G0/:R@FMLPT:QV& MCVTRYO34.@X7;QOGY-0T(N]O^^=TU#0 '[Z>R2FI==Q]X0W;EJ5636/PX7O3 MG)*:QMWB=]TY+36-N$<.*N2\U#3T%ATRR4FI:?#]TA&A+3EG-8VY+Q_[RBGZ M#C'XTCE@"&JWS^:8Z?J)^3)'+]__!U!+ P04 " "[.&51%L6%R,\0 !G MD@ % &5Y<'0M.&M?,C R,#$Q,#4N:'1M[3UK4^LXLI_OK;K_03>S9POJ M$L?.@Y#PV&("G,G..8%*,G=F]\LIQ5:(%L?V2#*0_?7;+=O!21S '" Y(7PA MMEZM5G>K7Y*/_G8_=@FY94)RWSLN6(99(,RS?8=[U\>%4 V+!X6_G?S/?Q_] M;[%(SB[:'7)J*W[+SKBT75^&@NWTONZ2MN=RCY$_?NY^(6>^'8Z9ITB1C)0* MFJ72W=V=X0RY)WTW5#".-&Q_7"+%8M)Q2S"*!>2,*D;T7Y.4S;)9M*RB6>U; MC:95;I8K1J56/CC8+_^?:39-,]7!_T<3(*F_)JD9IF$9-:N2JGA%[1MZS4C[ M+%6Q4K=KM.8TAE4VJ-;-^@%U#BSSH$:'M=I@6+/3D/K!1/#KD2([]JX&$>;K M>RJ"8!D],V0RH'NO.D1#)<.X?QHE1. M-G!Q(4ZH,0L?E@#'/]XTKI#=?&FSC.IV* 3(J$EVFZ0T XVV'WI*+&L7%68T MNP?9=C.#R[N*QJ35:#1*NG3* 4HLY=]&"4J3B@M=SG(Z%@^HG'(ZEWZU;-4? MDPU1C2G,DF=!#%6MTA]?O_3L$1O3XKQ X??+1K!0^J",1Q'_4%UEUW^H6E*" M>G+H@YQ!>8@]U8IFN5C>3W52A#68Z2A9DZ?Z.7A8I>7K@P*VH"4MHP[^'S-% M]=949'^&_/:XT/(]A=39!ZXH$#MZ.BXH=J]*NC4I83O%EPH;LX*9\X=+K>(KWJLN&,'FL;E6LJF66IU.:_BB<#*DKV5%I9IRGQJZF MQS[W #&3%@PNJ-OV'';_*YOD@^&A- L0_2Z%%(1+L"%#,;:)HK!XX+DX\!%'M#O1@(ATFL\7>![Z23%5-C"QY5Z-N_F$!_/E0HG1Z79 M^3S@86[B$2ZD'XH'5&@UHQGC7R_;4_C7[9*&3*]G_"YYR1U\/>1 XQHHELG/ MK?:OLXLYWS@9J90Q5#Q2 .ON.W/#@Q@3"I7'DZG66$LZ>2B;;0,J MPN/ %P!D4N',#P2W3KM_?D9Z_=/^>8]\Y\26+?4J)M8[;_W6;??;,*O3SADY_Z/URVGG M\SEI77[]VN[UVI>==YYM^2UG^_MI[Y=VYW/_LK-'SEI@S]6JC5>8WBP[@3'( M'6(:]27<%#=VV5 U*W6C7OF4O-*6)KZK-3XM%P;[K\=B^VM$B1>7W:]DN8YA MIG6,Q.>0TN">J5H<%'^=URD^,@%H=EL7[@1)U#WO]$GW_.JRV]\DN7,5"AG" M*Z)\TF,VFC31\ED5X@MBU7:<7>(/B1JQ39HV3#447''H\?S>'E'OFJ$_$6=J M-2K5[YWJ6A&O=F7"Q 0+?*'(3O+,*"B.3"K";M%)&A4S9[?YB*PK9\FZ*ZV/ MGD>Z:BZA1R([^K@ MG?3@=9C:#MRZ&0"P#&O<-+Q;]EX +I\;4_[.+<2\J5; M9+GZEC2VG&(JBQ9XEUUSB?VJ#I3DVR7/)^P*/<;D2KN,;18J;E,W=F_/D\<[ MBRSS+5&\Z0%J(&I[6X4<[S<1,WH-;9_ M%47K,IKC<0'T.)NYK@RHK6-.\7,\3_T\ TN3ALI/,&3[KDL#R9K)CT-RQQTU M J( 8+373VG;6SE)+U%YI6J89:QQ5%).5@7KL<**930:K]>Z%,.80'JKJ04H MQP\*WTM*:>+ Y]D%PQP$V9M>ZE%398I0GXA']\\Q@D<3Z]+X=^\=M M+?Q>0F_E_6*Y7J_"WV,$M[;[T)OZF7;T;H)F]R68VX+\'4Q4Z7!ME.?5Y:P? M:>*@SL[LJKNK$C[/FN6'D3UO2^PM?SSF4FXZ;>/&3"))N27K#T#6;:-K] QR M/@Y6+Z>+J[J4AC*2V&X\J6B[C]Y MD-OQ<6*6J_4%B_-]2>MM=X$81>BHO1*P0CR@+CF_9W:(.>OD<@A"D\D]0CV' M 8)HG#W>Q&0,V:^(MZ:"0@@.YT*1O.3T,Z^5=_-0<,$EU#3\/N2\-OR M\ 7\ BL\"K@($C_&G+U'^! #+=XU3C MT%748WXHW0F1H-[*X42WC!OX UC+2.N-DR/$0SPNA'X$B/9)4C;T71@X$#7(8M?L)J;P:.3PM&C(S6)?8K+,3 MKAJUZFM-.)M5>NS:9^2W-NE-QB#W7IU5C@!L+P%TE7 LW;)G?-"_"ZZ 0]%K M%'JQQ2F_+]PV\'UW0($U%0@(I(!&O5H]7/1+(Z*6Q4,6O!GK3.,Q#@%I*222 M()4"U@U!EE3+M5B&H?!*I4IAAM2.52>MBRXI5TP#*D9*JT:,MO<7K/VMY-I* MK@\GN6:<,ZBZV58*ANX1D^?:0![2-Q.1SF])=L!1@@LFBG M,/F4 F95G6)Y9[#[/&D6U=W*LY4O\U:>K9T\LQZ19VTI0R:V4NW=I%J%%:MX M60U9((Y,_B:/8FEMX+8E0B(:BXXV;\O-_X]I[[& M6?C?EX3_:HV7I3[&24))8S(;'I Z/& %BOP4G4G-V%<.-SCMIH\WG@"/;'2Z M#:/VB-@NE7*;2+;($4E0+)J(44_%R?2%9W/O^O'TD^>?'Q#T)&]M,B,)BNC8 M:#Z*M- =N.9$ M:[S;1QMBSH/X_[CJ;TEK2UHID5;/$FF)BR?W50\+#C;<1I.#T?T1(QTJ'?IG M)/;(5RINF")?OK2><:[P=4\DO.'5!>].V&W/0?\=(X,)L74N'8!Z SL[TR<2 MYQ+=N"34(PSP?(W!V6OAWZD1N@$#3'ZCDCALR+WH4HHHL\2L)8ZLN;22Z.*= MRM0)B)BL'^HD$[.VB_F7D0^Q/"B6,[K(O,1GKB]T*V+S7>.Q+%6=+OFR)-75 M+-EY-OHC4HP)N14-_(Y>]'R.T/5:MO;P$=[9 M X[)9$2^D&PZ C9C+K,5L)GG:^]Q*)FN!<#$*:T($8^\\OJN)D2['LN=X.!W M'(9&EO5@NE BV"V7T&XXO4:>VOI6:JR,%S4[5#@R2F9U'G5=5W;HU'6=YE'C MA>0YI8?L]<^YTZ[NPM$4$/KRKT4PLP;*'XB$,4?BP;2_9L6!8/2F2(> G"9U M[^A$QI=*O^-EL#KRG$9!*M\=GY%O2-JK,*<6/8&F%6A%D:!L][Y%EY1^:W>^ MG;6[YZW^9;?W[;+[[:K;[K3:5Z=?OEU>7&0%3E>AR;45&R=K%44EUP*LLH$7 M,J\10*@O+(*35M%K$:^O%=1=)D-7Z2-HER#UHX1I?>#LX>L@+1^V&2PPU@IT MDHJ2+Q$A_PJEXL/)RPY4/2VL\BH2MN_ZHIDX-E>H5LPLX,_4O@'%(O2<8@S@ MA?Z#>I=X7'OV;L4]\OCE>F0'=W$\#U8V#UN)E@E/UN$NF (R!$V @E* YQX% MPV/$#,C-@^%M?<8&:/%!H1 Q=:(B@MW^&>H[ZTBDL/18H"+8*F8$G"9E7& QR"NI,,#UP,PL$F"G#4'A'(9TT4B612OA326\?R/ M@I\3O"@W/9M7\P$\ZW+8S+M)$E.PK\9.1D48-:O;CML(>P=OQ6-$UYZ@.U3OP!A5RWIBUW@B06T?.\I,\V33^HD_J'N\UL+5QW MO?;GSFG_MZ[^%EE^@W[IAU-6P^+IK^-$<;<_0RYB]\7SHM![60$[)W0GQ*8A M!ME ,LCDVRPPS( 1">0'!;ZG?68#-J+N$.. V)'>D^,*Z+4*/6BCNP,;>^0+ M0).S]3Z\P/L RG-C__FG%:N-S=K,\EC!J5,M&XX (!*48<>%2N&QDZOF6Z'B M$0D^-[4P")BP03?/*=J7.8V>^,Q.ANJ>S#W6.[7@*,P1TI@[#F:WOCLK/;6^ MU<+C,-;>@=JS8'R^8818S,RXC^Z,BW) ORJEMHHOL5OCC4S[,Q<@NPC(BZG M 5?[F%CZ>=)\15K*/OGR8V,H[ZT'%:-Q\/&P5)(E\IGY HR#2X.I-GCN8"\(G:3YO\R\;E)&-B*Q:U8W(K%K LMMJN? P$;*!E; M(\Z&J73=Z+,10B?._<*H@S[F5OS9-$;.V"US_0"=TV]^YNU%09YW#RP=E0:^ M,]&S'ZFQ"S_^ U!+ P04 " "[.&51R-#17JLJ "0:P( $0 &5Y<'0M M97@Y.3%?-30N:'1M[7WK4^/&TO?W4W7^ASEDDP-5LK'D&X;-UN,%[X;G98$ MF[SYE!I+8UM967)T@77^^J=[9B3+QL9W+.1)G<."K][_Y^+F M_.&/VQ;YY>'+%;G]^O'J\IP<%(Z/?R^?'Q]?/%R(+RK%DDX>?.H&=FA[+G6. MCUO7!^2@%X:#T^/CIZ>GXE.YZ/G=XX>[XU[8=RK'CN<%K&B%UL&'?__K/7[& M_V74PG]#.W08_,*&@[# OC<:^I_52A&N@N^.XR_?'\>7_Z=0(->?R;GG/C(_ M9#YYK!9+1:-8+9%" 2]H>]80_OW7^P$)PJ'#?C[H4[]KNX6V%X9>_[0T",_D M)Z$WX'^&['M8L%V+N>%IZ<>SCN>&A0[MV\[P],'NLX!#L_?'@0^J-_('4L;ONJ6]W>\D+EQO"$\-[3]N>8XV-Z1R> MW/;MR;&(/W$ IZ[G]ZDC'AHBKSKP 7SJ,G'5(_5M"F\B\L*##ZWO/;MMAZ31 M*.H3DUF'?.>T#R.E4X'L-;HW]O]+@E\\^>#;K=K]*V_C$'?^*>$_^G% MOP;= \(%Z>># T*=$/^1:@-^AT=NC@A392C-W 7$ MR(3G,O_L(S6_=7TO?_K#)_[?^@(F'\=I5MJ^N W9K6>[(;GM4?C( M9%%HF]0)R'N\(9[_^)@./MRQ@>>' 7GHV;Y%?HTH5P!&R2B13[9+7=.F#KEC M0>3 1=2UR"\P/P?G&,#'2$+0&SX\@X:,7+!'YGB#/GP:O#_&UT[R?-ODS[IX M".;:(;S"3'-?C[D_34#&5_42(E$@#QZ\BOC %S<"BG@=\DZO%NL$7N* J>$< M=5E(!KYG168X?F6U>))<6,@0(TZ4?J1P+O(1>O__W'^]:'R5_F=8OD.6=[ZX[:@-TJZ1B@9>*'D?F!_+_3AEAX)@,W4=ID% M?'9LX" *!#S\T0Y!*AQ@;&@7?FM]_D3P[Q!5,@EAFBQ$(7F")4^[K. S!_2V M1DREX$NAR6O@3+HPRM %[CP$* FEY!?*^3R^H)T; :P(YP2"CPV6*61IZH_8C\P?7=]RR[PW7#%$U/3%C^8.?!G"-W MN>''F^ 7'24@&# S!/D"A5,@BMD[9#8->H1RPWQCAEX;='89."08%I)WY5*Q M2K[,L-:*+UOCRQ?J@B85^M4C/2\ S0J+RNTPG[DFK"_J.'Q%/;&V20.\RJ)# M9-G):;E$FE](ZR%3:G1)F/P7&")0+YL;X!2O:6D.KN5(_=Y\:-T]W/Q^K0%S M@Z"HD6O0D7U<<56YX H D6JELUDNET8N7;,HKCF\;MY?-'\]18O^<,3-^=C% M("O] 76'^&_?#M$:@QQ9PI.*53A^QWSTQ>Q_\#/;=;U'BGJ9>(->V*-.WS9C MU0ZOES(&5T4@@Q98Z]B5\Z4KA\H^[#'X/_I]$E42;CT ;@Y",=]R21N9A%[L M^<$EOG#]S,3ULU*N7_$5I66C"BE_LOS3#R>&43K[W0;(B.P&Q00 , (.IMV' M 8@2LM/K=&Q068]V8$MO'\6E/T XR!V)@<2& >JO/DIM#\!FV#.ISV(48@,/ MK,A',<4W2M$"2,+@?W 9:$4O\D%G)O#^8 Z0,"0T7X #VD#1?\1E(+5W?>,)TP2F+0 M&P8V: Q7"@4HE2!J_P5@$.]DCY[#\65,^\23 +J&OFUR(2E*!BAUD!5U\)X2 M%WR$GP_^;+8N;[Y> 1ZY0YWO,^L65N1'T C?^#<&1FOIAR\@YV+)C#2'1B:5 M2F(,^@.');H")*_K>19Q:!M-A <>Z@"\R! US.'GJ]LC$*3O-I*D.P3B1]:0 MK[,DA7M7\\1&A@P'@3_'4-H,!,$XI)@(R^.L0U%>1?!U@$,XTP>)21(OR2_2P MVT/^Z]?B?9%\0D)R#8BO:%I]4#*PSN2H/UTTQ8@=S^-.^A/UN@P&:1HBM1H >3$D>H!2ELA["'Y&-=E; CVW0ZXM0"L$1+0%7 /7.C: MH!N Y*",&9^9X[E=YD_"V=2JX''NY^MF,]M%N 7FQR\=(+O;*-$%V@$%?4J= M)SH,SL3^A%Z"UQQL=3MBF2VM]57-[G7+[&V&'8S& =4&LAOO0F1J;"23HQKI M2X\#OB"3H\PH[7H<#X,=<[RG; [1#C/*4,"U74"- 8A<)@=8S.2H ( 0:EFV MB-0_C3P['CT KP%@3>@,T4D#.\C1F,DCB BVI'O$O3:I\UL";,VN9><3<'' M&8NX1B:']RR8F\E1SMU8D/CG"46"*I;]2#@M?CYP6"=$ M%PSC5XRT/=]B_L\'I0-B,L<)!M0$ )_\/4!K)_^."2MN00HZ=!"PT_B7,S+A MY(4^_K#(HWPS$',B7ZU2U.L_GCWU[) 5\-5(C">?#@Y>TV';V-))\_F_$V+\ MWY>D]OUQ:+T)4DV7Z1ESW;F7N_UQ_?3#=UACQEE*8T[GY3[(\TQ &^L\4%Q3 M]AQXH!R3'@;@CV!0W\(-]\C%S9!!Y)L80+,P+I<$QP/2\;T^C].=BVT\-*=Z M_2S @%GHV^TH]/P \S$"C GZWG>[#\ ;@'FE6I*/!F7Y:UENLP5B.] 7(?^) M.\KI.PQ^1W&2W_##QQ^H4N%?T+9*YV921I7.53HW3_*\HLX5NYF+*%W:;T>. MV$<*(K^+.S\B-R8@A\W[\^!H#5VLU4O+:F-#TTM*'^='?I4^5OHX3_*\@#Z^ M9Z#;,'E+ZMDD89CZWT2>..WZC.L M>::/R L 7LEV]VC@_)UQJ)PZ!#D[2$_9\[O4M?^)$YM$ M10R^*E#:_*U*O]+F2IOG29X7T.:7+FE&79BTEL; DWF&F+2#"CR54@S*R[%Y MV#9."OZ+9RB*A$.9SB7U/"#=D8[OV6:/]$5N$W6)Y45MGKL(%^#8XRPPGGG( MW"[MHK:U;# +:!2X7DY%4G"@B..+Y$)DCR9IR%IJ @FF%WF26)Z"6=&!S%>U M74SK3"51QEEI,.>X\@78(W(TN=&!T0\\47@O8'Z<%2FR*^/T:DQ3LY&V/2\8 M8'5!/-XXYQ+&K:S%&UU=REHH:Y$G>5[ 6J1!=)PZP@%] J?[GFN'TB \3['G MNC,(/-"^7+>"ZH=/!5Q'X(_6Q;4DIL:,<3>(9!)L0#LL',;60=8>!-JD+6"@ MM[TA8XLJUG6X&O-P)I-159^>%,OE']6&\5KK]&940O)U8/$<)+4KG$TMHJRB MLHIYDN?%?"B9CZ?Q&BI+5,?YH70(L#P*DRPW@2_%"_KBH&+<8V'>;)[1/%/QS)PK[ -PS_]'FH;2KJW-R M"!\=\;H.[J/A!=@1 !VG93B#W@8T98P)#FT7Y*E/ M+29+[<"=]/O$\9 [<7213S_-0ML%%B(/74]46.)5XGD^/@\%QW-=)J:6$#UA MMXHXOE7MHJRELI9YDN?U(HXW9@3J#&LZN)ZE UXW':1:$H :Y=M)P4C'8S'S M=].) JS!!G<2'L FMZ"$K1D5@W.-RGRL"97[5ES)-@.;%LE7+&T5A9?)SE7R M."T]2*[G*1@H5@B!-.1=8Y14#@!@&)OBI'P;Q^*+-G@8,TSU9V 3,(#WYN(V MW'MR2=OG&TRT+XS!O1?!M?_/\QD5]=K<#/T5^79@R2KJ>&^-7\JP@PA.3CK@ M?'*=2+88Z8C2;3E<("J&,D#9APT97I%-I$BPD>/<7),T X+HN?%\\$ MW^C!U/F[GG.I"!(UI YO X!$ZD0A.OZQG1:165E:"T_F9DL:V%B !I$?1-*& MX^=37O*F(P+[[/_?_43[@[.+=!M)%0'(J@U0F$9AFCS)\Y(1@' L1AYO(U+R M^>KV>>\*M'7;:%X1\1P5A ]MVV-@16U4BA>13P. /;(73LC,GBM&$S>[:'ZY M&$^5 0C$3 %7.F#;>1.+ZXNQ3A6)/_KIHAEO]7:\R(=/XPY18PUM1DTE>A%0 MG)@. WL:25Z3,3 "+>6@Y[GXZXO;\4@7CSJ>B%;7[UV=SLU^9Z3\M<[B[](;19#?Z1'.A8,6+IU,A2D"ZR2EE&C_" 1RGWQU:H!X0Y7 M^G5JT7)62?<]T(B?1 9$Q,&1O<%XF&.Y)<<5!'SUKE%L3-<(>FKQ22QC>CYV M-/;$;D0,:>!+K@B4T.Q.:&1: #8; YB*TK*J/.CU629"KQ5KDQ(!JM"36TIB MJPHQ,V]O)KMCHFJW?,#J+J]!0K%*/V340]/$SK^@Q7B 2Q-75J9>^9F'0)KQ M3(4]*,UX;!POB2]N,[Z1UND$+)0C2IN^T;89-FCCL;;QC'[Y'-#WGEOP)JFN MH^-3!>.8*)K:<-K%P.U"M5$;&@7L!;!ZW MGI0/@+]*'GM1F[Q9KZ9OC@>4D@FI(I1JR!R^O@8WFGP10A-C[?U&UBY29%5@ M;=13>'1<:^HI?=I9^%WS@/4BHY68OU(T1@MW#CX.EAHB5PPG(P!1?.&$@WU< MZ#L&C@O!Q84$:62BRB-AFG0@3UZ&BS*51:'%W4O*"VAQ.7&HZBGO0:0(54LK MHL215VV)+GPW],_C)I:\FR7[.[(?,3$P MY"<2/.NE&,OKSES825'4XB*3=_#4R"8O-!V.X[W)(.R MN']IV@,>9'Z6J#6> 31*=A(#&QU2@X696(,D3A(Q*1CF:#S+-AGSR"X-'(J& M$!8KSPRF01#U^8EGWEB;^K2IG)F4+6CTY$6.E20$\YW+CB @HE-^(*,IBIA2 M%:+#B2-48IL6<2T %YLTI!C1YBUL^%8ID,5D%G_O0'10Y/T5QMLIO"FUH39E MU<$B,P\6*8N#1;+59W9V,6008)^35/<0KO3@FH#YCR)I C59Z@R1/N@7H47P MN) !GJXLDC]'A6]A#WC>[4VOK"QFL.?M/B.%\]%1?N>83GOI\BZW(>\VO3\+ M/$E\?@)X.^N80W[LG :^<>0'_+?)@_.TB7,/>:_ZP(RDK5OC<#IY!E&RRF"I MCAU)1QZ\I&N1. OT(,+M1J%=+]5%;.6Z*^7EAU*46 M1>M^6"OK1^1$+Q3[':X$+U2->I&I4B:!-/&DJ,D.2_:<.LCM1V>+"O+U,3I1/": M.\0V7.D$;+R<*CFY#QX&6(7A6,>T,A<.BYDRXG8JSI@&(/BL[W\O# >GQ\=/ M3T]%-F0#%!-QQF$1H*-49SAVGP%,&\8C&)L$K_^:-I-GXU0NU$S%N&U5V&Q[ M4?CRR9?Y=J->/N^3'$Y? 4>\2]GVC_U$IP;((Y,Y9>,S/+231&Z?A8!,+/YF M5Q99]I@S('8?;G]DLL[B46;BR)X,XA$!1KVB(#X&C.?6!^.YI;SHD;=ZZV%- MRE.Z(B89W^G8^8TBO;9C^VA)!GP0ELB&]<3);+&_F!B#T?E$'6S9$TI=_\BX M$TK[?7EL>5*2&K^(BCWF H_AC3W&!"3F @F!Z2!9':XB8:;)@8C"T^"2Z41FT[$MRFVD8,LSI%#)WBY(^2+,X_/Q"718]22MET46O^.SG;H M/;GBX%UJ]J* A;$8RG,H\<*/-/B&8[BSK2[3N%+^7Y!)-N1F'BRN[XJ^5!0U M5CITD!AZ[J O:O ./KQHV^1:Y66]:+<>GG!!^_SC*]O]QJQ+5YFM'>KMA;W3 MBO!.[YN?6N27YMW'FSMR_]!\:'UI73_7?X&'Y/[UOG7 MN\N'R]8]N8)_/C\P(_U^?^;A)_TPANR(I(5AI/RQ@9XPD^KJ7) M*)XF G'8"@&4"US/#T7S< !)/0&O!]12&JL-2]3U "G;8 CEJ<"C@8DEC)V" MQ"ND@" /*/M@\,C!UT#>%LF]UT^.'>T 43!S MES-7D,VD$0JG&4:IP\.YV];II!HF $T3-RD=!8[O@.&DH[V2B? 'RAN>*9N^ M"2X&!H'\<*N M)M8&&/R@8UF<2%PPHVOA7C9Q(])1"*AN\C41@GCTB<4_U21 M2F1"R$XP]L"SE!1AKB!?1,A'T+Z.>"6BC;'RF$!+6 TD[D1.?!E^ O)!SV+I M2CUB5+4K01,\YXP/A;9%1Q#>PJO'UQY\W[%%$67ZY&XWW;\7P2"/Y?.FAF>D MXT3(:W&I)-LHS"[9^>R-0<0?B(7(0RGHX-M&:+%M>31PC ;_QLI>$=N'^3S; M)> DF7C@>'7UM KPV#N?,C".=D1#,;?'JXVP\CSF5'ID !A84^$L!G\A:1 M((Q$Y=OC\"OE^_>CYIDOUZ<+)DY1!^)"CA&YJ/$R=%XEQ?R"%$B>Q"*)15GCH$" MT\9H8-E ']!+D_LO:H=C^ZAQ%S Q[0WLX/VQ@698*,.34BZ^M,X J0$W?)KL M>J;4F]<6VFVT/Y'JW1[;A\3,B-4B2FWLI.VZS^Q^.P)&F@Y9#0LY05)R*D D; >V87!)GX_ .$0[2R>-Z.(@WD^(N2_E#<MOZK\!K+#9 +X>?*\_[3H5\ZQF+KZB/+TPWOM=&%TBVCW\+ M2M)";"BZ+&-XV>XB$ &2I= S1K58:"<;8P+TC7D.(W8GXC6B?LR746WPV->I M-W4CVQ+ 2'O6;Y2S-01B,;@'[@Y'L6_T5QR'"3R+X1B BZ)E#7WT;$M$V:9= M@N@ ON4T/\,^<&A&Q3._L2'NW0<8 7#.$J#OV%+@SC L!PK1Y[N+@>?88J!G MHJI<]-[F;&0N^!J>*YN&.?2)D\2-$)B+IM@N"C@N" (>BK)L)Q*#H^V 20Y8X Z"(%G!68JKL;=@ ML<#T[78*K<,KW&XP*B>_Q\9V=N*>MKZ+]FH8E.G;_.3G(OD==V)<] .[$05U M&3(V2E:)W8C)K)%E_ B,4\[T(Y*M%(R!@=ZR<+\"-;3L5"OGFEZ%,(R Q3YX MVEGBRW/<89HQ[@SY4> (]O@S'.4D)4T+9L_S#R^* M1]_F 6&1R8O[<[RCTA"^QV5J6SR$]X+0P,-N7G9.@P' -5"^F#Z4]NT8-Z_" M;L%'0^[%8EB(KP,P6;@..&U#^HWQ47AM!Q4N=PH\V6\9'AOQ)KI(!,"QMI2^ M%T:$8)?8'2X_OBW6=]*D:=3U\!L/6(/'*BB$L2%WF*)SS)U$\B:$#2QH+_U: MOKQP4NDEEI-,A[>7T!!B &.?LA?B_?#@]'W;)\!:X1(5[B)TD6C%H+:G1J=&IT:G39&YW: MPIG'-'&X]H:R4J;2?W5*>4GKSZ:%M_M&YO+J\?R.TOS;LOS?/6 MUX?+\^;5O48NK\^+I'E]0>Z_?KR_O+ALWF%:T5Q<_>;8='YS?7]S=7G1?&A= M_#G*KOKS_.;+[5WKE];U_>5OK3^O;B2W5KL-KKZ CUH7)'U?.IGKYA.YN6W= M\8RM^[=/WL.O+HTLS)\Z>@%XOIG97&(9H@XW# ME^\;'M_2$U31R\4JUZIC?97[MF4Y[("0CY_/;ZYN[GX^D 9OHG-VN5$TEE7] M\D_>AA[_'N<9?C#3^TK8\UIIEW?-Z\^M_S3UTTM#*F%113"]&_7"5)L@V0IR M/I^(BP=K7Z3JZNV[G],)1@"R#(0J'RQ-,Z->+%7V@&X/O*F<[ _&^X+-H*&Q M/ W+Q=+D:LTC"5\4O)"W1*0::Y(7'XF2*;9@9 M:1=C$O-T!%(JUN'!A,\0^YZX8?[,T89LSDKTRZ.@;\DVO43?44 VY[0=JW+> MM.E2$KQ=$Z',DSJ0[I& MY&A_%Z1,4^N%C+/28-YQXDN(C=+_:^DOM>@VIL"JBI8OP^"3HOX""MXNYM7K MF2#5;?K8 WYNSIP5O"S678]*QI;4N$*=DO_OTK5!Z9]5K5X]6486=H8]UY:. M%]6L0H7S)&6LNDS72J4&60([YA8I*EPX1V[TBJ97=;*DCGFK\K&4DME;Y$86 MTC(G6J,R)CB9#',*A)<]&E_%W;LF3RU-]?-:SPM^L[!0A2=G2DU#JY:K\Y1U M5L.3V]7>*I0X4VH #E8K"\#!A35+C@"B"B7.E!I=JS9*ZRN;MRHJ*NZWJK;1 MC>KZN' O G]W_/1Z?C2+UV?+^+)O%MTI+"=Y7Y&-Q1:E54YQFT)IL3Q4:LM@ MM-PB,H6_8CM:K]"+1(1 MU\Y#5 GVKY.O&-,99S\U$WG#VU6J-C805LRSKNPX(I N;E(PNG5*O M59?;TEXHAIEK>5TMUJE$=&41K6OETJ0/MUK --=RN8' JA+2-:+Z];*1]?!L M-FAUDYQIB2>AN,'\JB15@_36PL ;L[)9S,?,16!VY9ED,KM1A4.W6=F2D7!H M)HFE0JR;K%HQ:L6*2FN<WXX.F&94//OR/;Y07 A M=;O\6$D:!&Q6UJ,J_%:%W]O=6CDYF;L?KS(K56;EF-24C?K&8Y)O4H!47N7B M,J.5:^7U-K=S:E6T MTOP<^7T B0H2)N:].^?#%FK$55G8!(UK^MQ6(ZK^>W/UWTK^YLJ? M*N[>8G&WDK_GZ=^5#6C O$O=!DNWE0C.$\&-16GWO963]ZR.>\E8;I;7],YI MO'+,5VF"69J@KM6JLXJ17@@,9UE,7S^ K,1KEGC5M.JSI)5EH\RYEK5%HM%* MO&;M:@&0J:X2LJ\+< MN\?1*LR]%HT/=:U1K1^I3J.<.CO_T@UXK+=7];E\3YMY4"O+&#&,6TX5SD1*\ M\DPRF:*KTG"WH%6REH6;26*IS-Y-=A_=;5> C!+O)NPQ7QZE20[E5O_1O);M MJC' MJ.1^0!6F2[BSVFA_OK@*]N%\ZHX_G4!6F9KXS-)/E5OOU,0MP^0[=(- MF<^"D)?;>RG\IA&7J7:=>0MW[9Q:AY5Y>QX9 G6JW'[KF9#/VNF\F4B>*K;? M1FK99%.NK(;X7E<_["V2JS4V<%+B?@;C$F0GXW J"K>'4;B=T^\0B^HF M5FA/]>?@;=ZJJ*B X:I1":U\TMA*(MQ^ MUZ]X+L!/+/R.[*"'!P!A&R>+M6=$%J<[0!NL6\G"(MU8:7;^U^5//YP8NK$4 M_?:\-F352I ]E:7%:;F/-1XK5G3LJ2S-U4MYEY^M5%CG7Y@.R]J)7EH??&:U MG+J<#3++3D1\BUN&1!?9XU8UU5F)G\9TQME/516JT.NE(.S8E&VDM$5PLOENJ&*ME^Q:%L)Z=)"6M>JI?IKQ+(M+\(. M_$8Q]['L:Q82QPO6[%HZDUYYC5J/37BO%^4[@EY^25\^^753,O3V#,4"H6PE M8(F "?**GX=Z5:M5E@+3\Z%SOB1OA5BW$K98V,BAT= :1G59;99WH5HW *XD M;&0OR6&EII5/RKN)B^\?M"4#YH, ]_N>2X(>3)842)L&MLDKPRS;B4)F;3I6 MGB]$O%)K4+7F1VL^C6'(8:E8VD"#O'TV.2LU"E4".153S_J);I/OO_%',(O21^;3+ MQF!^0+PH#$( ^7@\U_*8?UL(/YKYNC&8!C96>Z4Q\#6B7%=H^H]\*M!,R_Y0Z3W08G$DL M52HMVPAK,V.W6OD\OJ\2)K7%^3^Z\?[RXO+YMUEZQZ (S[H0X[8='YS?7]S=7G1 M?&A=_/FQ>=6\/F_]>?]+J_5P+QFT\)5PP47K^KYU0=*7$GDI$9>2MT^[PZ\N MC2QPGZRC'$SFTB5ASXL"ZEK!T21W5AK^=)]N4@.^)3L%7B&1CC>ZMWR?!1U& MZ6C_?% Z("9ST$TW;;>;_#V@EA7_+>*T'E@M=O)*E6>#4+6;S.?E$O:G@O( M"R= [J^ 7#!3RH>N/8LQ/M>3!J_06UQ/QO>OU+34VM149%M-7;U.1& M[HR245)2]PH&0TG=F-3IC+RI4\_R19/SR$=D02C7D7-.HLW7U)DKN-G\:)5C=J\])?7Y3.3":P;D6T\I.5NE IV%IR96B&7EG[[+CF M:7H1F(/4>;\^,QE8B;;#@@4:(N^E7=CGI=K0RN.',,X1BK>ACO>9H[JNE<=+ M3C(75\V(MKSUV8#:5MPO/JTUS;'(@D+7"@(M2;*J=E*>IU<5\,T?UQN-^OJJ M=W<;JQG1S)?N(XS&\X>+!\#J%"/Y81,?FC2 J##@7KM3+9178S1%'RUJIK@#H(L&#D+I= M&ZL9A69,M1W&S0\8;OI"T4 -AW M4JD W0:(J**X2DCF[]"5-K _-]->[JH)>9I*.TC?%B'?U4*]>TZZ]?#9LN?H MJL:IKY:BFOY9KVGUAKZT(['6TG@;YDI)]MN3[+JA->KZ(E9T:M>D?-;C7=FT M;3MV:,LTPB#TS&\]& ?S@Y]^.#'T^AFOUPGGI+3DBRHJIKOAPL6WH=451S,? MI=^Q8H@KMYV1VIQ3OIUWBJA [5:4IPK/YY[KJO1OK/1O0(>\DRNB4&J:?L1& M%2XJ1T1AE5T%071#*Y5+*B-%R<\2,J-K)6/].N\]J&6\&2M;3,%JE?>B$-:R M>V3C-6P*5>\!SRLG"T5TLYKQDA$M?,$Z##2P17SVR-R(J;07E?:R];3@THS. MS2KK1%!@WRFG MPG:;".UJ)5W5-"HQF2\FI?6##@O7'^W+ 8\B'KQ&''C7]-NY8&ZF!$RM]\E" M]X:FKY"BL0>60LG2\DT3M%IE_=2/?&G^^YG%>^J,017G5-5[>\31S 6N,Y+I M=DX'-L!C%9!6HBU#4#,CJK1IFE$_Z.?U!S[K M,3>P'QFQ7?A[7GE&ENB:#;*J(-Q6R'I2F5<7K:*Y2I"6%R25]+'ZOM^J#=SV MGGQJ2W\#1,3#K^:>/)!_"Z#$9(Z^U\KE5\S\V)>FS,\R/]9JZ:G(JWI>9T); MO&J[)Z*:7BO1SH]HSVIZ?1QBLSWXS+(?9U#YKR@([<[P[",UOW5]+W*M@J37 M)_[?? :,T?O'1252GY#(YS8$GZ\;@VDBL-HKC6>+H.U9PP__!CKUPKX#O_P? M4$L! A0#% @ NSAE40=K9H'(! \Q8 !$ ( ! M &5Y<'0M,C R,#$Q,#4N>'-D4$L! A0#% @ NSAE4:K* \P5!P BDD M !4 ( !]P0 &5Y<'0M,C R,#$Q,#5?;&%B+GAM;%!+ 0(4 M Q0 ( +LX95&2,5J;"P4 XL 5 " 3\, !E>7!T M+3(P,C Q,3 U7W!R92YX;6Q02P$"% ,4 " "[.&51%L6%R,\0 !GD@ M% @ %]$0 97EP="TX:U\R,#(P,3$P-2YH=&U02P$"% ,4 M " "[.&51R-#17JLJ "0:P( $0 @ %^(@ 97EP="UE A>#DY,5\U-"YH=&U02P4& 4 !0!& 0 6$T end